CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME

Brief summary (registry, in English)

This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.

What you commit to

• Study type: Interventional · Phase 3
• Planned participants: 240
• From 9 Feb 2026 to the primary completion date, Oct 2027
• 70 sites in 5 countries
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (70)

Sites in registry order. Pick your city on the disease page to sort them by distance.